Shared conversation on NexusTrade
Top Biotech Stocks: A Quarterly Rebalancing Strategy
Explore a dynamic investment strategy focused on the top 5 fundamentally strong biotech stocks, rebalanced quarterly using StockReport ratings and market capitalization.
User: What are the most fundamentally strong biotech stocks?
Aurora: Below is a concise, easy-to-scan summary of every ticker returned by your query (all rows included). I kept the table to the most important columns: latest report rating, market cap, P/E (TTM), most recent quarter revenue & net income, and the computed 3‑yr CAGRs for Revenue / Net Income / FCF. Ticker symbols link to the requested nexus trade pages. | Ticker | Rating | Market Cap | P/E (TTM) | Latest quarter revenue | Latest quarter net income | Rev CAGR 3yr | NI CAGR 3yr | FCF CAGR 3yr | |---|---:|---:|---:|---:|---:|---:|---:|---:| | [ZTS](https://nexustrade.io/stock/ZTS) | 4.5 | $66.8B | 26.51 | $2.22B | $631M | 6.0% | 6.9% | 9.8% | | [RMD](https://nexustrade.io/stock/RMD) | 4.5 | $41.9B | 31.87 | $1.29B | $365M | 13.6% | 29.1% | 27.6% | | [DXCM](https://nexustrade.io/stock/DXCM) | 4.5 | $31.7B | 59.27 | $1.04B | $105M | 18.1% | 55.0% | 127.9% | | [ISRG](https://nexustrade.io/stock/ISRG) | 4.5 | $172.0B | 69.48 | $2.25B | $698M | 13.5% | 10.9% | -9.1% | | [REGN](https://nexustrade.io/stock/REGN) | 4.0 | $60.7B | 13.49 | $3.03B | $809M | -4.0% | 0.6% | -17.5% | | [HALO](https://nexustrade.io/stock/HALO) | 4.0 | $7.96B | 16.41 | $265M | $118M | 31.8% | 3.3% | 16.3% | | [CORT](htt…
User: Create a strategy to rebalance to the top 5 most fundamentally strong biotech stocks every 3 months. If there’s a tiebreaker, use market cap to break it
Aurora: Description: This portfolio rebalances every three months (90 days) into the top 5 fundamentally strongest biotech names chosen from the biotech universe we discussed. Selection is driven first by the latest StockReport (fundamental/analyst) rating — a direct measure of fundamental strength — and any ties are resolved by market capitalization (larger market cap wins the tiebreak). The universe used for runtime selection is the full biotech list from our prior analysis (listed below). At each rebalance the strategy picks the 5 highest-ranked tickers, sells/buys as needed, and allocates equal weight to each selected name. To avoid over-trading it enforces a 90-day cooldown since the last buy or sell for the assets. This keeps the portfolio disciplined and systematic: it continually favors names with the strongest fundamental reports while using market cap to break ties. Initial portfolio value defaults to $10,000. Use this as a ruleset for automated rebalancing — the backend will compute the StockReport ratings and market caps at rebalance time and then apply the equal-weight reallocation among the top 5. Full stock universe (for selection at runtime): ZTS, RMD, DXCM, ISRG, REGN, HA…